Skip to content

Exercise and Nerve Function in Diabetes

Effectiveness of an Exercise Program on Nerve Function and Cutaneous Nerve Fibers in Adults With Type 2 Diabetes

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00970060
Enrollment
26
Registered
2009-09-02
Start date
2008-06-30
Completion date
2009-10-31
Last updated
2013-07-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Neuropathy

Keywords

neuropathy, diabetes

Brief summary

The purpose of this study is to describe the effect of a 10-week exercise program on nerve function and number of nerve fibers in the skin in the lower leg in people with diabetic neuropathy.

Detailed description

The objective for this application is to quantify the benefits of exercise on nerve function including proprioception, and investigate the relationship of these findings with improvements in epidermal and dermal innervation. In this pilot project, we will pursue 2 specific aims: 1) determine the effect of an exercise intervention on nerve function in people with diabetic neuropathy, and 2) assess changes in cutaneous innervation following participation in an exercise program.

Interventions

BEHAVIORALExercise

Supervised moderately-intense exercise, including both aerobic and strengthening activities. Sessions are 3-4 days per week for 10 weeks.

Sponsors

Patricia Kluding, PhD
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
40 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Age 40-70 * Type 2 diabetes * Peripheral neuropathy

Exclusion criteria

* Serious cardiac history or other medical problems that would prevent safe participation in exercise

Design outcomes

Primary

MeasureTime frame
Quantitative sensory testing10 weeks
Nerve conduction studies10 weeks
Proprioception10 weeks
Dermal and epidermal nerve fiber densities10 weeks

Secondary

MeasureTime frame
Clinical assessments of neuropathy, pain, body mass index, muscle strength, and glycemic control (glycosylated hemoglobin or A1C)10 weeks

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026